Literature DB >> 3708595

Growth of human urological tumors on extracellular matrix as a model for the in vitro cultivation of primary human tumor explants.

K Pavelic, M A Bulbul, H K Slocum, Z P Pavelic, Y M Rustum, M J Niedbala, R J Bernacki.   

Abstract

The goal of this study was to establish an optimal in vitro growth assay system for human urological tumor explants. Bovine corneal endotelial cell extracellular matrix (ECM) coated dishes were evaluated as a growth substrate for tumor cultures. Growth success for different urological carcinomas (prostatic, bladder, kidney, and testicular) was compared after seeding fresh surgical explants onto bovine corneal endothelial cell ECM and plastic culture flasks. Tumor samples were disaggregated enzymatically, and 1 X 10(4) cells were seeded onto the different substrates using RPMI 1640 medium containing 10% fetal calf serum and/or different growth factors, nutrients, and hormones. Cell growth on ECM was quantitated on days 7-15 by [3H]thymidine uptake, cell counting, and total protein. Tumor cells were characterized by flow cytometry and cytology. It was observed that ECM provides superior culture conditions for urological carcinomas. By increasing the initial number of cells plated on ECM and by adding different growth factors or hormones, the growth rate for specific tumor types was increased significantly. Several tumors (11 cases) grown on ECM were examined under the light microscope, and in all cases pre- and post-cytology confirmed malignancy. Tumor cells maintained on ECM and transplanted into nude mide retained their tumorigenic and morphological characteristics. Clinically aggressive tumors were associated with extensive ECM degradation. In addition, the growth of fresh human tumors on ECM provides a biologically relevant model system (for assessing the invasiveness of tumors in vitro) and should also be useful for drug evaluation studies.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3708595

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  Presence of oestrogen receptors on target cells and antiproliferative activity of estramustine phosphate: positive correlation for human tumours in vitro.

Authors:  J Pavelić; I Zgradić; K Pavelić
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

2.  Collagenase derived from human fibrosarcoma is responsible for degradation of basement membranes.

Authors:  N Slade; S Levanat; S Spaventi; K Pavelić
Journal:  Int J Exp Pathol       Date:  1991-12       Impact factor: 1.925

3.  Connective tissue protein in the prostate gland.

Authors:  T Nakada; Y Kubota
Journal:  Int Urol Nephrol       Date:  1994       Impact factor: 2.370

4.  Expression of growth hormone receptor, plakoglobin and NEDD9 protein in association with tumour progression and metastasis in human breast cancer.

Authors:  Emil Štajduhar; Mirela Sedić; Tanja Leniček; Petra Radulović; Aleksandar Kerenji; Božo Krušlin; Krešimir Pavelić; Sandra Kraljević Pavelić
Journal:  Tumour Biol       Date:  2014-03-28

5.  Xanthofibroma of the adrenal gland.

Authors:  T Nakada; I Sasagawa; T Yamaguchi; H Sumiya; T Oki; J Shimazaki; O Matsuzaki
Journal:  Int Urol Nephrol       Date:  1992       Impact factor: 2.370

6.  In vitro degradation of extracellular matrix by human ovarian carcinoma cells.

Authors:  M J Niedbala; K Crickard; R J Bernacki
Journal:  Clin Exp Metastasis       Date:  1987 Apr-Jun       Impact factor: 5.150

7.  Establishment and characterization of a new human colon adenocarcinoma cell line: BCS-TC2.

Authors:  J Turnay; N Olmo; J G Gavilanes; J Benitez; M A Lizarbe
Journal:  Cytotechnology       Date:  1990-01       Impact factor: 2.058

8.  A new and reliable culture system for superficial low-grade urothelial carcinoma of the bladder.

Authors:  Hans-Helge Seifert; Andrea Meyer; Marcus V Cronauer; Jiri Hatina; Mirko Müller; Harald Rieder; Michele J Hoffmann; Rolf Ackermann; Wolfgang A Schulz
Journal:  World J Urol       Date:  2007-04-18       Impact factor: 3.661

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.